Sagimet Biosciences has amended its articles of incorporation and bylaws as part of its Series A common stock IPO. This move authorizes creation of 500,000,000 Series A and 15,000,000 Series B common stocks, and also permits reclassification of outstanding common stock as Series A. It eliminates references to previous preferred stock series and allows issuance of 10,000,000 undesignated preferred shares. Also, procedures relating to stockholder proposals and director nominations were established.